Concepedia

Milos Dokmanovic

MD

17

Publications

2.4K

Citations

16

H-Index

1999

Active since

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Memorial Sloan Kettering Cancer Center

National Institute on Alcohol Abuse and Alcoholism

National Institutes of Health

Milos Dokmanovic is an author at Center for Drug Evaluation and Research specializing in medicine, cell biology, and cell signaling.

Top concepts

Publications per year

1999–2018

17

Publications

17

A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents.

Bey-Dih Chang, Eugenia V. Broude, Milos Dokmanovic et al. · PubMed · 1999 · 546 citations

, , +20

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

Johanna Ungerstedt, Yoshihiro Sowa, Weili Xu et al. · Proceedings of the National Academy of Sciences · 2005 · 504 citations · Full text

, , +20

Histone sumoylation is a negative regulator in <i>Saccharomyces cerevisiae</i> and shows dynamic interplay with positive-acting histone modifications

Dafna Nathan, Kristin Ingvarsdottir, David E. Sterner et al. · Genes & Development · 2006 · 325 citations · Full text

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

Weisheng Xu, Lang Ngo, Gisela Perez et al. · Proceedings of the National Academy of Sciences · 2006 · 179 citations · Full text

, , +17

Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers

Nishant Mohan, Jiangsong Jiang, Milos Dokmanovic et al. · Antibody Therapeutics · 2018 · 150 citations · Full text

, , +15

Rows per page

1–5 of 17